Use of cell-free fetal DNA in maternal plasma for noninvasive prenatal screening. Clin Perinatol 2014 Dec;41(4):957-66
Date
12/03/2014Pubmed ID
25459783DOI
10.1016/j.clp.2014.08.013Scopus ID
2-s2.0-84910116657 (requires institutional sign-in at Scopus site) 14 CitationsAbstract
Noninvasive prenatal testing (NIPT) using cell-free fetal (cfDNA) offers potential as a screening tool for fetal anomalies. All pregnant women should be offered prenatal screening and diagnostic testing based on current guidelines. Adoption of NIPT in high-risk pregnancies suggests a change in the standard of care for genetic screening; there are advantages to an accurate test with results available early in pregnancy. This accuracy decreases the overall number of invasive tests needed for diagnosis, subjecting fewer pregnancies to the risks of invasive procedures. Women undergoing NIPT need informed consent before testing and accurate, sensitive counseling after results are available.
Author List
Wagner AJ, Mitchell ME, Tomita-Mitchell AAuthors
Aoy Tomita Mitchell PhD Professor in the Surgery department at Medical College of WisconsinMichael Edward Mitchell MD Chief, Professor in the Surgery department at Medical College of Wisconsin
Amy Wagner MD Professor in the Surgery department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Chromosome DisordersChromosomes, Human, Pair 13
Chromosomes, Human, Pair 18
DNA
Down Syndrome
Female
Genetic Testing
Humans
Predictive Value of Tests
Pregnancy
Prenatal Diagnosis
Trisomy
Trisomy 13 Syndrome
Trisomy 18 Syndrome
